Share price of Exactech Inc reached a new 52-week high of $25.86 on Jun 14. This represents a strong one-year return of approximately 23.5%, much better than the S&P 500’s return of -1% over the same period.
Currently, Exactech has a Zacks Rank #2 (Buy). The stock has a market cap of 359.87 million and a long-term expected earnings growth rate of 8.9%.
Growth Catalysts
Exactech reported impressive first-quarter 2016 results. Adjusted earnings of 31 cents per share beat the Zacks Consensus Estimate by a penny and increased almost 7% on a year-over-year basis.
The growth was driven by strong revenues, which increased 6.4% (7% at constant currency) to $65.3 million. All three major segments -- Extremities, Knee and Biologic & Spine -- reported revenue growth in the quarter.
Exactech noted that the full launch of proximal humeral reconstruction stem and investments in the U.S. sales organization helped in improving the company’s results. These along with the upcoming launches of three revision systems will drive growth in 2016 and beyond.
Encouraged by the impressive results, Exactech raised its full-year 2016 guidance. The company now expects revenues in the range of $250--257 Million. Adjusted earnings are forecasted in the band of $1.14 to $1.19 per share.
Estimate Revisions
However, the positives outweigh the negatives as evident from the recent trend of estimate revisions. The Zacks Consensus Estimate for fiscal 2016 increased by a penny to $1.17 over the last 60 days. Similarly, fiscal 2017 estimates increased by a couple of cents to $1.33 over the same period.
Key Picks
Better-ranked stocks in the broad medical sector include Masimo Corp (MASI - Free Report) , IRadimed (IRMD - Free Report) and CryoLife . All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Share price of Exactech Inc reached a new 52-week high of $25.86 on Jun 14. This represents a strong one-year return of approximately 23.5%, much better than the S&P 500’s return of -1% over the same period.
Currently, Exactech has a Zacks Rank #2 (Buy). The stock has a market cap of 359.87 million and a long-term expected earnings growth rate of 8.9%.
Growth Catalysts
Exactech reported impressive first-quarter 2016 results. Adjusted earnings of 31 cents per share beat the Zacks Consensus Estimate by a penny and increased almost 7% on a year-over-year basis.
The growth was driven by strong revenues, which increased 6.4% (7% at constant currency) to $65.3 million. All three major segments -- Extremities, Knee and Biologic & Spine -- reported revenue growth in the quarter.
Exactech noted that the full launch of proximal humeral reconstruction stem and investments in the U.S. sales organization helped in improving the company’s results. These along with the upcoming launches of three revision systems will drive growth in 2016 and beyond.
Encouraged by the impressive results, Exactech raised its full-year 2016 guidance. The company now expects revenues in the range of $250--257 Million. Adjusted earnings are forecasted in the band of $1.14 to $1.19 per share.
Estimate Revisions
However, the positives outweigh the negatives as evident from the recent trend of estimate revisions. The Zacks Consensus Estimate for fiscal 2016 increased by a penny to $1.17 over the last 60 days. Similarly, fiscal 2017 estimates increased by a couple of cents to $1.33 over the same period.
Key Picks
Better-ranked stocks in the broad medical sector include Masimo Corp (MASI - Free Report) , IRadimed (IRMD - Free Report) and CryoLife . All the three stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on MASI - FREE
Get the latest research report on IRMD - FREE